Abstract 2251: Serglycin proteoglycan promotes progression and metastasis of triple-negative breast cancers
Authors: Cameron N. Johnstone, Nathaniel Harris, Marie Ranson, Anil K. Rustgi, Robin L. Anderson
Journal: Cancer Research (2015)

Abstract Introduction. Triple-negative breast cancers have a propensity to metastasize and a poor outcome relative to other breast cancer subtypes. No molecularly targeted therapies exist for triple-negative disease and the standard of care for remains surgery followed by adjuvant radiotherapy and/or chemotherapy. Therefore, new therapies that target the molecular alterations present in triple-negative tumors are needed to either prevent metastatic dissemination or kill micrometastatic lesions at distant sites. The serglycin gene encodes a large secreted proteoglycan decorated with chondroitin sulfate modifications and expressed primarily by the hematopoietic system.1 While serglycin was recently shown to be expressed by mammary epithelial cells2, its role in breast oncogenesis is unclear. Methods. Serglycin expression was analyzed by RNA-based (qRT-PCR) and protein-based (immunohistochemistry) methods3. Serglycin expression was specifically knocked down in triple-negative breast cancer lines (MDA-MB-231_HM4, SUM159) by shRNA technology using the pGIPZ lentiviral system. Genetically engineered cells were assessed in vitro using standard assays. Tumor growth and spontaneous metastasis to lung, liver and spleen was analyzed in vivo by orthotopic inoculation of cells into Nod.Scid.IL-2Rgamma-null (NSG)5 immuno-deficient mice. Results. Serglycin was found to over-expressed in a subset of triple-negative breast cancers as well as in several metastatic triple-negative/claudin-low breast cancer cell lines including MDA-MB-231, SUM159 and Hs578T. Knockdown of serglycin was engineered in highly-metastatic MDA-MB-231_HM (231_HM) cells and in a metastatic variant of SUM159 cells. In vivo experiments showed that knockdown of serglycin reduced the growth rate of primary 231_HM tumours implanted in the mammary fat pads of mice. Moreover, following resection of the primary tumours, spontaneous metastasis to lung, liver and spleen was reduced in serglycin-depleted 231_HM cells. Conclusions. The hematopoietic proteoglycan serglycin is over-expressed in a subset of triple-negative breast cancers and may represent a novel target for anti-cancer therapy. References: 1. Korpetinou A, et al., Serglycin: at the crossroad of inflammation and malignancy. Front Oncol. 2014 3:327 2. Korpetinou A, et al., Serglycin is implicated in the promotion of aggressive phenotype of breast cancer cells. PLoS One 2013 8:e78157 3. Li XJ, et al., Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis. Cancer Res. 2011 71:3162-3172 4. Chang XZ, et al., Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer. Breast Cancer Res. 2007 9:R76 5. Shultz LD, et al., Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol. 2005 174:6477-6489 Citation Format: Cameron N. Johnstone, Nathaniel Harris, Marie Ranson, Anil K. Rustgi, Robin L. Anderson. Serglycin proteoglycan promotes progression and metastasis of triple-negative breast cancers. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2251. doi:10.1158/1538-7445.AM2015-2251